{"id":5136,"date":"2019-05-27T12:49:09","date_gmt":"2019-05-27T07:19:09","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5136"},"modified":"2025-05-06T12:10:22","modified_gmt":"2025-05-06T06:40:22","slug":"meet-the-worlds-most-expensive-drug-zolgensma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma","title":{"rendered":"Meet the World’s most expensive drug: Zolgensma"},"content":{"rendered":"\n

The U.S. FDA recently approved the much talked about Novartis\u2019s drug Zolgensma for treating a life-threatening condition Spinal Muscular Atrophy <\/a><\/strong>(SMA).\u00a0 SMA is a neuromuscular disorder that worsens the muscles over time. It happens due to a mutation in the SMN1 gene that results in the deficiency of an SMN protein, which is essential for the functioning and survival of motor neurons. SMA is a leading genetic cause of death in infants. With time the disease leads to difficulties in breathing, paralysis and even death of the babies born with Type 1- the most severe type of SMA<\/a><\/strong>.
Zolgensma is a gene therapy that is designed to deliver a working SMN1 gene to facilitate the transcription of functional SMN protein for better functioning of motor neurons. The drug is enveloped by a shell of a genetically engineered virus, the adeno-associated virus (AAV) 9. The SMN1 gene in Zolgensma comprises a double-stranded DNA, which is responsible for producing a standard copy of SMN1 to motor neurons, which further produces healthy SMN protein. It also has a transgene that ensures the production of SMN protein is sustainable and life-long. <\/p>\n\n\n\n

Zolgensma, priced at USD 2.125 million one time, and USD 425,000 per year for five years, is the costliest drug present in the market. Approved for the treatment of children under the age of 2 years, including those who have not yet started to show symptoms, Novartis claims to have treated around 150 patients with Zolgensma. Without a doubt, Novartis is going to face many backlashes from the critics for pricing a medicine several thousands of dollars. The availability of the life-saving drug is useless if it is not affordable.  However, Novartis defends itself, claiming Zolgensma is a one-time treatment and is more effective than other available ones that are long-term therapies. 
The cost factor is not the only hurdle Zolgensma has to cross. There is also a competition. Zolgensma is going to compete with Biogen\u2019s Spinraza which got approved in 2016 for the treatment of all types of SMA<\/a><\/strong>. Zolgensma may have the upper hand as it is a one-time treatment unlike Spinraza, which requires regular spinal infusion worth USD 750,000 on the first year and USD 375,000 annually life-long. Roche is not far behind. The drugmaker is also developing a pill for SMA known as risdiplam to set its foot in the Spinal Muscular Atrophy market<\/a><\/strong> by 2020. <\/p>\n\n\n\n

Although, clinicians trust the lifelong treatments as promised by Zolgensma. However, it is still too early to say that. Many researchers are also stressing upon the need for early Spinal Muscular Atrophy diagnosis<\/a><\/strong>. Early diagnosis is crucial to provide infants with the right treatment at the right time. Thus, Novartis is focusing on genetic testing of the newborn at the time of their birth.<\/p>\n","protected":false},"excerpt":{"rendered":"

The U.S. FDA recently approved the much talked about Novartis\u2019s drug Zolgensma for treating a life-threatening condition Spinal Muscular Atrophy (SMA).\u00a0 SMA is a neuromuscular disorder that worsens the muscles over time. It happens due to a mutation in the SMN1 gene that results in the deficiency of an SMN protein, which is essential for […]<\/p>\n","protected":false},"author":1,"featured_media":5141,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[830,2356,258,423,524,2031,3607,3747,3619,3608,3609,3618,4221],"industry":[17225],"therapeutic_areas":[17229,17238,17234],"class_list":["post-5136","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-biogen","tag-biogen-spinraza","tag-gene-therapy","tag-novartis","tag-roche","tag-spinal-muscular-atrophy","tag-spinal-muscular-atrophy-market","tag-spinal-muscular-atrophy-market-trends","tag-spinal-muscular-atrophy-news","tag-spinal-muscular-atrophy-pipeline","tag-spinal-muscular-atrophy-therapeutic-market","tag-spinal-muscular-atrophy-treatment","tag-zolgensma","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nMeet the World's most expensive drug: Zolgensma -<\/title>\n<meta name=\"description\" content=\"Zolgensma, priced at USD 2.125 million one time, and USD 425,000 per year for five years, is the costliest drug present in the market. Approved for the...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Meet the World's most expensive drug: Zolgensma -\" \/>\n<meta property=\"og:description\" content=\"Zolgensma, priced at USD 2.125 million one time, and USD 425,000 per year for five years, is the costliest drug present in the market. Approved for the...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-27T07:19:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T06:40:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021241\/My-Post.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Meet the World's most expensive drug: Zolgensma -","description":"Zolgensma, priced at USD 2.125 million one time, and USD 425,000 per year for five years, is the costliest drug present in the market. Approved for the...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma","og_locale":"en_US","og_type":"article","og_title":"Meet the World's most expensive drug: Zolgensma -","og_description":"Zolgensma, priced at USD 2.125 million one time, and USD 425,000 per year for five years, is the costliest drug present in the market. Approved for the...","og_url":"https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-05-27T07:19:09+00:00","article_modified_time":"2025-05-06T06:40:22+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021241\/My-Post.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma","url":"https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma","name":"Meet the World's most expensive drug: Zolgensma -","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021241\/My-Post.jpg","datePublished":"2019-05-27T07:19:09+00:00","dateModified":"2025-05-06T06:40:22+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Zolgensma, priced at USD 2.125 million one time, and USD 425,000 per year for five years, is the costliest drug present in the market. Approved for the...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/meet-the-worlds-most-expensive-drug-zolgensma#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021241\/My-Post.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021241\/My-Post.jpg","width":2560,"height":1440},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021241\/My-Post-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Biogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Biogen Spinraza<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">spinal muscular atrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Spinal Muscular Atrophy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">SPINAL MUSCULAR ATROPHY Market Trends<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Spinal Muscular Atrophy news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Spinal Muscular Atrophy pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Spinal Muscular Atrophy therapeutic market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Spinal Muscular Atrophy treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Zolgensma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biogen<\/span>","<span class=\"advgb-post-tax-term\">Biogen Spinraza<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">spinal muscular atrophy<\/span>","<span class=\"advgb-post-tax-term\">Spinal Muscular Atrophy market<\/span>","<span class=\"advgb-post-tax-term\">SPINAL MUSCULAR ATROPHY Market Trends<\/span>","<span class=\"advgb-post-tax-term\">Spinal Muscular Atrophy news<\/span>","<span class=\"advgb-post-tax-term\">Spinal Muscular Atrophy pipeline<\/span>","<span class=\"advgb-post-tax-term\">Spinal Muscular Atrophy therapeutic market<\/span>","<span class=\"advgb-post-tax-term\">Spinal Muscular Atrophy treatment<\/span>","<span class=\"advgb-post-tax-term\">Zolgensma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on May 27, 2019","modified":"Updated on May 6, 2025"},"absolute_dates_time":{"created":"Posted on May 27, 2019 12:49 pm","modified":"Updated on May 6, 2025 12:10 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5136"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5136\/revisions"}],"predecessor-version":[{"id":31694,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5136\/revisions\/31694"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5141"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5136"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5136"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}